Akebia Therapeutics, Inc. [NASDAQ:AKBA]: Analyst Rating and Earnings
Equities traders oftentimes stay updated on what leading stock market analysts say about a potential stock purchase. When it comes to Akebia Therapeutics, Inc. [AKBA], the most recently available average analyst rating is from the quarter that ends in December. On average, stock market experts give AKBA an Outperform rating. Its stock price has been found in the range of 5.20 to 11.60. This is compared to its latest closing price of $8.05.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Akebia Therapeutics, Inc. [AKBA] is sitting at 2.14. This is compared to 1 month ago, when its average rating was 2.12.
For the quarter ending in Dec-18 Akebia Therapeutics, Inc. [AKBA] generated $0.06 billion in sales. That’s 18.76% lower than the average estimate of $0.07 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Wed 8 May (In 36 Days).
Fundamental Analysis of Akebia Therapeutics, Inc. [AKBA]
Now let’s turn to look at profitability: with a current Operating Margin for Akebia Therapeutics, Inc. [AKBA] sitting at -74.64 and its Gross Margin at +95.83, this company’s Net Margin is now -69.10%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -40.26, and its Return on Invested Capital has reached -23.00%. Its Return on Equity is -38.02, and its Return on Assets is -19.49. These metrics suggest that this Akebia Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Akebia Therapeutics, Inc. [AKBA] has generated a Total Debt to Total Equity ratio of 2.36. Similarly, its Total Debt to Total Capital is 2.30, while its Total Debt to Total Assets stands at 1.35.
What about valuation? This company’s Enterprise Value to EBITDA is -4.28. The Enterprise Value to Sales for this firm is now 3.14, and its Total Debt to Enterprise Value stands at 1.05. Akebia Therapeutics, Inc. [AKBA] has a Price to Book Ratio of 1.02.
Shifting the focus to workforce efficiency, Akebia Therapeutics, Inc. [AKBA] earns $639,206 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 8.17 and its Total Asset Turnover is 0.28. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.33 and its Current Ratio is 1.76. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Akebia Therapeutics, Inc. [AKBA] has 121.55M shares outstanding, amounting to a total market cap of $850.85M. Its stock price has been found in the range of 5.20 to 11.60. At its current price, it has moved by -39.66% from its 52-week high, and it has moved 34.62% from its 52-week low.
This stock’s Beta value is currently 1.46, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 39.59. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Akebia Therapeutics, Inc. [AKBA] a Reliable Buy?
Akebia Therapeutics, Inc. [AKBA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.